Here is some more on Poseida Balance sheet.... huge difference compared to Imugene....they are already generating revenue.$130m worth for 9 months 2024 From their company website:
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024PDF VersionStrong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patientsIntroduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignanciesOn track to deliver further updates across allogeneic CAR-T pipeline before year-end 2024, including presentations at the 66th American Society of Hematology Annual Meeting in December
IMU Price at posting:
3.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)